312 related articles for article (PubMed ID: 34179717)
1. Cancer models in preclinical research: A chronicle review of advancement in effective cancer research.
Sajjad H; Imtiaz S; Noor T; Siddiqui YH; Sajjad A; Zia M
Animal Model Exp Med; 2021 Jun; 4(2):87-103. PubMed ID: 34179717
[TBL] [Abstract][Full Text] [Related]
2. Organoids technology for advancing the clinical translation of cancer nanomedicine.
Zhao DK; Liang J; Huang XY; Shen S; Wang J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1892. PubMed ID: 37088100
[TBL] [Abstract][Full Text] [Related]
3. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
[TBL] [Abstract][Full Text] [Related]
4. Could 3D models of cancer enhance drug screening?
Brancato V; Oliveira JM; Correlo VM; Reis RL; Kundu SC
Biomaterials; 2020 Feb; 232():119744. PubMed ID: 31918229
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development.
Arnal-Estapé A; Foggetti G; Starrett JH; Nguyen DX; Politi K
Cold Spring Harb Perspect Med; 2021 Dec; 11(12):. PubMed ID: 34518338
[TBL] [Abstract][Full Text] [Related]
6. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
7. 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor-on-a-Chip.
Li W; Zhou Z; Zhou X; Khoo BL; Gunawan R; Chin YR; Zhang L; Yi C; Guan X; Yang M
Adv Healthc Mater; 2023 Jul; 12(18):e2202609. PubMed ID: 36917657
[TBL] [Abstract][Full Text] [Related]
8. Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold.
Hu LF; Yang X; Lan HR; Fang XL; Chen XY; Jin KT
Exp Cell Res; 2021 Nov; 408(2):112858. PubMed ID: 34600901
[TBL] [Abstract][Full Text] [Related]
9. Novel patient-derived preclinical models of liver cancer.
Bresnahan E; Ramadori P; Heikenwalder M; Zender L; Lujambio A
J Hepatol; 2020 Feb; 72(2):239-249. PubMed ID: 31954489
[TBL] [Abstract][Full Text] [Related]
10. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies.
Magré L; Verstegen MMA; Buschow S; van der Laan LJW; Peppelenbosch M; Desai J
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220953
[TBL] [Abstract][Full Text] [Related]
11. A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening.
Zhang L; Liu F; Weygant N; Zhang J; Hu P; Qin Z; Yang J; Cheng Q; Fan F; Zeng Y; Tang Y; Li Y; Tang A; He F; Peng J; Liao W; Hu Z; Li M; Liu Z
Cancer Lett; 2021 Mar; 500():87-97. PubMed ID: 33309780
[TBL] [Abstract][Full Text] [Related]
12. Bladder Cancer Patient-derived Organoids and Avatars for Personalized Cancer Discovery.
Kim YS; Hsieh AC; Lam HM
Eur Urol Focus; 2022 May; 8(3):657-659. PubMed ID: 35915037
[TBL] [Abstract][Full Text] [Related]
13. Modeling neoplastic disease with spheroids and organoids.
Zanoni M; Cortesi M; Zamagni A; Arienti C; Pignatta S; Tesei A
J Hematol Oncol; 2020 Jul; 13(1):97. PubMed ID: 32677979
[TBL] [Abstract][Full Text] [Related]
14. What role could organoids play in the personalization of cancer treatment?
Francies HE; Garnett MJ
Pharmacogenomics; 2015; 16(14):1523-6. PubMed ID: 26485224
[TBL] [Abstract][Full Text] [Related]
15. Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model.
Horst EN; Bregenzer ME; Mehta P; Snyder CS; Repetto T; Yang-Hartwich Y; Mehta G
Acta Biomater; 2021 Sep; 132():401-420. PubMed ID: 33940195
[TBL] [Abstract][Full Text] [Related]
16. 3D modeling in cancer studies.
Atat OE; Farzaneh Z; Pourhamzeh M; Taki F; Abi-Habib R; Vosough M; El-Sibai M
Hum Cell; 2022 Jan; 35(1):23-36. PubMed ID: 34761350
[TBL] [Abstract][Full Text] [Related]
17. From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities.
Aleksandrovic E; Zhang S; Yu D
Clin Exp Metastasis; 2024 Jun; 41(3):187-198. PubMed ID: 38430319
[TBL] [Abstract][Full Text] [Related]
18. Organoids in lung cancer: A teenager with infinite growth potential.
Xu Y; Xin W; Yan C; Shi Y; Li Y; Hu Y; Ying K
Lung Cancer; 2022 Oct; 172():100-107. PubMed ID: 36041323
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived organoids as a model for tumor research.
Wang J; Feng X; Li Z; Chen Y; Huang W
Prog Mol Biol Transl Sci; 2022; 189(1):259-326. PubMed ID: 35595351
[TBL] [Abstract][Full Text] [Related]
20. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
